TABLE 5.
Model predicted PASI90 response of treatments at different time points.
| Drug | Regimen | PASI90(%) a | ||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | ||
| TNF-α inhibitor | ||||||
| Adalimumab | 80 mg 0 40 mg 1, q2w | 6.10 (0.69, 18.00) | 30.30 (12.10, 48.59) | 43.50 (27.11, 55.00) | 48.05 (35.70, 58.20) | 50.60 (42.70, 59.90) |
| Infliximab | 5 mg/kg 0, 2, 6, q8w | 10.40 (2.45, 26.80) | 36.80 (14.81, 54.20) | 49.15 (31.81, 61.00) | 53.40 (40.60, 63.80) | 55.90 (46.80, 65.00) |
| Etanercept | 50 mg biw | 1.16 (0, 4.73) | 9.90 (2.90, 20.10) | 22.00 (10.60, 31.00) | 28.95 (18.20, 37.89) | 34.40 (25.90, 42.50) |
| Certolizumab pegol | 400 mg 0, 2, 4 200 mg q2w | 2.29 (0, 7.70) | 20.00 (6.95, 34.40) | 36.50 (21.10, 47.70) | 43.50 (31.51, 53.40) | 47.80 (39.20, 55.80) |
| IL-12/23 inhibitor | ||||||
| Ustekinumab | 45 mg 0, 4, q12w | 2.64 (0, 8.55) | 22.90 (8.72, 38.10) | 41.60 (24.91, 52.80) | 48.85 (37.20, 58.10) | 53.30 (45.00, 62.10) |
| Briakinumab | 100 mg q4w | 5.83 (0.71, 16.50) | 37.10 (16.41, 54.90) | 54.85 (37.11, 65.90) | 60.80 (48.81, 70.20) | 63.60 (54.40, 71.40) |
| IL-23 inhibitor | ||||||
| Guselkumab | 100 mg 0, 4, q8w | 11.7 (3.08, 30.09) | 47.45 (23.60, 65.49) | 61.00 (42.50, 72.10) | 65.40 (52.30, 74.50) | 67.40 (58.70, 75.50) |
| Tildrakizumab | 100 mg 0, 4, q12w | 2.21 (0, 6.88) | 18.10 (7.01, 31.10) | 34.80 (19.40, 45.40) | 40.70 (29.90, 50.50) | 44.90 (36.70, 53.90) |
| Risankizumab | 150 mg 0, 4, q12w | 5.11 (0.41, 15.60) | 42.15 (19.60, 60.79) | 65.50 (47.80, 75.70) | 72.70 (61.41, 81.40) | 76.70 (69.70, 84.00) |
| IL-17 inhibitor | ||||||
| Secukinumab | 300 mg 0, 1, 2, 3, 4, q4w | 10.60 (2.04, 26.30) | 47.95 (23.92, 65.90) | 62.50 (46.10, 73.30) | 66.70 (56.10, 75.80) | 69.30 (61.40, 77.50) |
| Ixekizumab | 160 mg 0, q4w | 21.60 (6.91, 47.79) | 55.35 (30.00, 72.70) | 67.20 (49.91, 77.20) | 71.10 (60.10, 79.50) | 73.10 (65.00, 80.60) |
| Ixekizumab | 160 mg 0 80 mg q4w | 18.40 (5.91, 45.10) | 50.40 (24.01, 67.80) | 62.60 (45.40, 74.20) | 66.95 (55.20, 76.00) | 69.40 (60.71, 77.00) |
| Brodalumab | 210 mg 0, 1, 2, q2w | 19.90 (5.81, 44.50) | 52.15 (27.00, 70.49) | 64.50 (47.31, 75.00) | 68.60 (57.30, 78.20) | 70.80 (62.80, 79.00) |
| PDE4 inhibitor | ||||||
| Apremilast | 30 mg b.i.d. | 0.38 (0, 2.14) | 2.68 (0, 6.36) | 6.09 (1.45, 11.50) | 9.75 (4.23, 15.30) | 16.40 (9.99, 22.60) |
| JAK inhibitor | ||||||
| Tofacitinib | 5 mg b.i.d. | 1.99 (0, 6.89) | 12.00 (3.29, 22.60) | 19.50 (9.94, 29.40) | 23.40 (14.00, 31.70) | 25.10 (17.60, 32.50) |
| Tofacitinib | 10 mg b.i.d. | 3.52 (0.03, 10.60) | 21.40 (7.96, 36.40) | 33.60 (18.70, 44.50) | 38.15 (26.80, 47.10) | 40.70 (31.60, 49.10) |
| Baricitinib | 10 mg qd | 3.05 (0.08, 10.50) | 17.20 (5.53, 30.10) | 26.20 (13.30, 36.20) | 29.95 (18.90, 38.70) | 32.30 (23.90, 40.60) |
| Dihydrofolate reductase inhibitor | ||||||
| Methotrexate | 20 mg qw | 0.85 (0, 3.59) | 6.27 (1.19, 13.80) | 13.05 (5.76, 20.70) | 17.00 (9.42, 24.30) | 20.10 (12.50, 27.10) |
PASI, Psoriasis Area and Severity Index score; PASI90, ≥90% reduction from baseline Psoriasis Area and Severity Index score; TNF, tumor necrosis factor; IL, interleukin; PDE, phosphodiesterase; JAK, Janus kinase; NA, not available; s.c., subcutaneous; p.o., oral; qw, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; biw, twice weekly; qd, once daily.
a
Data are shown as median (95% CI).